CAR T cells: driving the road from the laboratory to the clinic
- 13 December 2013
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 257 (1), 91-106
- https://doi.org/10.1111/imr.12126
Abstract
Blockbuster antibody therapies have catapulted immune-based approaches to treat cancer into the consciousness of mainstay clinical research. On the back of this, other emerging immune-based therapies are providing great promise. T-cell therapy is one such area where recent trials using T cells genetically modified to express an antibody-based chimeric antigen receptor (CAR) targeted against the CD19 antigen have demonstrated impressive responses when adoptively transferred to patients with advanced chronic lymphocytic leukemia. The general concept of the CAR T cell was devised some 20years ago. In this relatively short period of time, the technology to redirect T-cell function has moved at pace facilitating clinical translation; however, many questions remain with respect to developing the approach to improve CAR T-cell therapeutic activity and also to broaden the range of tumors that can be effectively targeted by this approach. This review highlights some of the underlying principles and compromises of CAR T-cell technology using the CD19-targeted CAR as a paradigm and discusses some of the issues that relate to targeting solid tumors with CAR T cells.Keywords
This publication has 117 references indexed in Scilit:
- Engineering T Cell Function Using Chimeric Antigen Receptors Identified Using a DNA Library ApproachPLOS ONE, 2013
- CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic LeukemiaPLOS ONE, 2013
- Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular SignatureImmunity, 2011
- Treating cancer with genetically engineered T cellsTrends in Biotechnology, 2011
- Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedCancer Treatment Reviews, 2010
- Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical TrialMolecular Therapy, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in HumansTransplantation and Cellular Therapy, 2010
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Preclinical development of T cell receptor gene therapyCurrent Opinion in Immunology, 2009